On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Cerus Corp. (NASDAQ: CERS) Partners with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

Company: Cerus Corporation (CERS)
Category: News

Shares of Cerus (NASDAQ: CERS) are up 15% following news of the company’s agreement with the Central California Blood Center (CCBC). CCBC will manufacture for Cerus a pathogen-reduced cryoprecipitate (cryo), a blood product used in the control of bleeding associated with acquired fibrinogen deficiency. “Cryo is a natural extension to our current FDA-approved INTERCEPT Blood System for Plasma. Following approval of a proposed premarket approval (PMA) supplement, INTERCEPT Plasma may be further manufactured into cryoprecipitate, for which we plan to seek an extended 5-day post-thaw storage claim. Given today’s growing emphasis on, and use of, coagulation monitoring and fibrinogen supplementation in improving outcomes in acutely bleeding patients, an extended-storage cryo product can potentially address an opportunity that we believe represents a market larger than INTERCEPT Platelets in the U.S.,” Cerus president and CEO William ‘Obi’ Greenman stated in the news release.

To view the full press release, visit: http://nnw.fm/E1ir4

About Cerus

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. To learn more, visit www.cerus.com.

More from NetworkNewsBreaks

Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Says Cigna will Cover ThyGenX® Nationwide

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Shares Surge on Details of Recent Meeting with FDA Regarding Intravenous CAP-1002

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Research Published in the European Journal of Pain

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217